Neonc Technologies Holdings NTHI

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for intracranial malignancies, particularly aggressive brain cancers such as glioblastoma and meningioma, as well as secondary brain tumors from metastases. The company's core activities center on creating novel drug delivery methods to overcome the blood-brain barrier, enabling therapeutic agents to reach brain tumors more effectively. NeOnc leverages its lead compounds, NEO100 and NEO212, which are derived from perillyl alcohol and designed for intranasal or oral administration to enhance central nervous system penetration.

NeOnc generates revenue through the advancement of its product candidates toward clinical development and potential regulatory approval, though it currently has no commercial products or sales. The company's value stems from its pipeline of NEO100 and NEO212, which are being tested in clinical trials for conditions including recurrent malignant glioma, meningioma, brain metastases, and Parkinson’s disease. Revenue generation is contingent upon successful trial outcomes, FDA approvals, and future licensing or partnership agreements, with no current revenue from product sales.

The company operates through the following segments:

• NEO100 Development: This segment focuses on the research, preclinical testing, and clinical development of NEO100, a purified form of perillyl alcohol administered via intranasal delivery. NEO100 has received Fast Track status and Orphan Drug Designation from the FDA for the treatment of malignant glioma. Clinical trials are ongoing for recurrent IDH1/2-mutant astrocytomas and malignant skull-based meningioma, with plans to evaluate NEO100 in combination with levodopa for Parkinson’s disease.
• NEO212 Development: This segment encompasses the development of NEO212, a covalently conjugated molecule combining temozolomide and perillyl alcohol, designed to improve blood-brain barrier penetration and overcome resistance mechanisms like MGMT-mediated DNA repair. NEO212 has received Investigational New Drug (IND) approval from the FDA and Orphan Drug Designation for glioma, brain metastases from breast cancer, and nasopharyngeal carcinoma. Clinical trials are evaluating oral and intranasal delivery for primary and metastatic brain tumors.

NeOnc holds a niche position in the competitive central nervous system therapeutics industry as a pioneer in nose-to-brain and conjugate-based drug delivery platforms for brain tumors. The company differentiates itself through its proprietary use of perillyl alcohol derivatives and integrated technologies such as AI-driven compound modeling and magnetic 3D bioprinting for preclinical validation. While large pharmaceutical firms like Merck (Temodar), Roche (Avastin), and Novocure (Optune) dominate standard glioblastoma care, NeOnc focuses on early-stage innovation targeting delivery barriers and treatment-resistant tumor phenotypes.

NeOnc serves patients with intracranial malignancies, including those suffering from recurrent glioblastoma, IDH1-mutant astrocytoma, meningioma, and brain metastases from lung, breast, or melanoma. The company also targets individuals with neurodegenerative conditions such as Parkinson’s disease in preclinical studies. Its customer base consists primarily of patients enrolled in clinical trials, healthcare providers administering investigational therapies, and potential future partners in oncology and neurology.